29 Nov 2019 12:05
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Bionow Double Award Win
Manchester, UK - 29 November 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it has won Bionow Investment Deal of Year and Bionow Company of the Year at the 18th Annual Bionow Awards ceremony, held at The Mere Golf Resort & Spa in Cheshire yesterday.
The Bionow Investment Deal of Year, sponsored by QIAGEN, is an award presented to a Company who delivered a significant financial deal in the period 1 August 2018 - 30 September 2019, involving companies that are active within the biomedical / life science sector. Yourgene was awarded it for its acquisition of Elucigene, a Manchester-based molecular diagnostics manufacturer and developer, for an enterprise value of £8.8m, which took place in April 2019.
The Company was also acknowledged by winning Bionow Company of the Year Award, sponsored by AstraZeneca.
The awards brings together leaders in the North of England's life sciences industry and recognises life sciences companies, academics and health organisations for their application of cutting edge technologies.
Lyn Rees, CEO of Yourgene Health plc, said: "I am so proud of the Yourgene team to be recognised for our achievements over the last 12 months by our biotech peers by winning two awards at the prestigious Annual Bionow Awards ceremony."
Yourgene Health plc Lyn Rees, Chief Executive Officer Barry Hextall, Chief Financial Officer Joanne Cross, Director of Marketing
| Tel: +44 (0)161 669 8122 investors@yourgene-health.com
| |
Stifel Nicolaus Europe Limited (Sole Corporate Broker) Nicholas Moore / Matthew Blawat / Ben Maddison
| Tel: +44 (0)20 7710 7600 | |
Walbrook PR Ltd (Media and Investor Relations) Paul McManus / Lianne Cawthorne
| Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com Mob: 07980 541 893 Mob: 07584 391 303
| |
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.